Evidence map›Paper›PMID 38132164›Full record

ArticleCells2023

Trans-Regulation of Alternative

Trine V Larsen, Christoffer T Maansson, Tina F Daugaard, Brage S Andresen, Boe S Sorensen, Anders L Nielsen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. CDK12 and CDK13 in oncology: from RNA regulation to therapeutic targeting.Cellular oncology (Dordrecht, Netherlands) · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Trine V LarsenDepartment of Biomedicine, Aarhus University, 8000 Aarhus, Denmark.
Christoffer T MaanssonDepartment of Biomedicine, Aarhus University, 8000 Aarhus, Denmark.ORCID 0000-0002-3071-3437
Tina F DaugaardDepartment of Biomedicine, Aarhus University, 8000 Aarhus, Denmark.
Brage S AndresenDepartment of Biology and Molecular Biology, Southern University of Denmark, 5230 Odense, Denmark.ORCID 0000-0001-7488-3035
Boe S SorensenDepartment of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark.ORCID 0000-0002-9472-8099
Anders L NielsenDepartment of Biomedicine, Aarhus University, 8000 Aarhus, Denmark.ORCID 0000-0003-4372-9961
Aarhus University · DKUniversity of Southern Denmark · DK

Funding

Direktør Emil C. Hertz og hustru Inger Hertz' Fond naInge og Jørgen Larsens Mindelegat NAKnud og Edith Eriksens Mindefond NAKræftfonden NAStiboFonden NA
6 · The paper itself

Abstract

Immunotherapy using checkpoint inhibitors targeting the interaction between PD-1 on T cells and PD-L1 on cancer cells has shown significant results in non-small-cell lung cancer (NSCLC). Not all patients respond to the therapy, and PD-L1 expression heterogeneity is proposed to be one determinant for this. The alternative processing of

Indexed as

B7-H1 AntigenCarcinoma, Non-Small-Cell LungCyclin-Dependent KinasesLung NeoplasmsHumansPolyadenylationRNA, MessengerRNA Processing, Post-TranscriptionalB7-H1 AntigenCD274 protein, humanCDK12 protein, humanCyclin-Dependent KinasesRNA, MessengerCDK12IFN-γimmunotherapylung cancerPD-L1splicing

Identifiers

PMID38132164
PMCPMC10741404
OpenAlexW4389784590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.